How iGRO™ works

iGRO™ is the only medical device that gives evidence-based predictions for the first 12 months of growth hormone (GH) treatment, using pre-treatment data. Getting started is simple and all patient data is stored securely online. Standard baseline patient data can be entered before treatment begins and results are displayed in a clear, graphical format. iGRO™ enables you to make highly accurate growth predictions based on gender, age and condition of patients, and evaluate response after 12 months: helping you to manage patient expectations and optimise the treatment outcome.